Two compounds.

The 22nd , teams such as the Kyoto University Center for iPS Cell Research is clear With the addition of induced pluripotent stem cells of human (iPS cells) , you have found two compounds that can efficiently produce a population of cells is the basis of the kidney was on .
The majority of renal tissues are made on the basis of the cell population of intermediate mesoderm . Compared with the conventional method in quality using an unstable protein expensive and low culture costs , this time , a shortened incubation period .
Team has been able to from the intermediate mesoderm of changing from iPS cells by using this compound , to produce the tubules of the human kidney , it is expected to lead to regenerative medicine to implant the cells and tissues of " kidney I have the " Ru .
Team examined were cultured in addition one by one to iPS cells compound of about 1800 species that were seen as promoting differentiation into intermediate mesoderm , you can either change the intermediate mesoderm . Then after 6 days in two of them , produced a intermediate mesoderm at a high rate of 75% or more . Only about 20% had not been changed in the same period in the conventional method .
It succeeded in culturing with embryonic kidney cells of the mouse the intermediate mesoderm , to form a portion of the tubular structure of the renal tubules further . I think the task of identifying the two compounds from 1800 kind it was very . By all means, I hope that it will lead to regenerative medicine of the kidney at an early stage .



京都大ｉＰＳ細胞研究所などのチームは２２日、ヒトの人工多能性幹細胞（ｉＰＳ細胞）に加えることで、腎臓のもとになる細胞集団を効率よく作製できる２種類の化合物を見つけたと明らかにした。
　腎臓の組織の大半は中間中胚葉という細胞集団をもとに作られる。今回の方法は、高価で品質が不安定なタンパク質を用いる従来法に比べ、培養コストを低く抑え、培養期間を短縮した。
　チームは、この化合物を使ってｉＰＳ細胞から変化させた中間中胚葉から、ヒトの腎臓の尿細管を作り出すことに成功しており、「腎臓の細胞や組織を移植する再生医療につながると期待される」としている。
　チームは、中間中胚葉への分化を促進するとみられていた約１８００種類の化合物をｉＰＳ細胞に一つずつ加えて培養し、中間中胚葉に変化するか調べた。するとうち２種類では６日後、７５％以上の高い割合で中間中胚葉を作り出した。従来法では同じ期間で２０％程度しか変化しなかった。
　さらにこの中間中胚葉をマウスの胎児の腎臓細胞と一緒に培養し、腎尿細管の管状構造の一部を作ることに成功した。1800種類から２種類の化合物を特定する作業はたいへんだったと思います。ぜひ、早い段階で腎臓の再生医療につながっていくことを期待します。